Reni Benjamin
Stock Analyst at Citizens
(1.35)
# 3,628
Out of 5,157 analysts
163
Total ratings
36.76%
Success rate
-14.46%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMX Immix Biopharma | Initiates: Market Outperform | $23 | $10.13 | +127.05% | 1 | Mar 9, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $2.50 | +100.00% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $5.42 | +84.50% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $5.38 | +123.05% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $71.86 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.30 | +564.45% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.19 | +428.82% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $97.10 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $7.61 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.73 | +445.93% | 5 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $2.15 | +86.05% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.14 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.36 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $15.81 | -36.75% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $24.98 | -7.93% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.33 | +50.15% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.39 | +198.19% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.90 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $15.72 | +154.45% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.41 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.09 | +29.45% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.14 | -12.47% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $46.26 | +29.70% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.71 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $148.14 | +112.64% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $73.84 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $227.72 | +16.37% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.11 | +313.63% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $10.38 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.36 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $29.19 | -58.89% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.91 | - | 1 | Nov 15, 2017 |
Immix Biopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $23
Current: $10.13
Upside: +127.05%
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $2.50
Upside: +100.00%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $5.42
Upside: +84.50%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $5.38
Upside: +123.05%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $71.86
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.30
Upside: +564.45%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.19
Upside: +428.82%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $97.10
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.61
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.73
Upside: +445.93%
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $2.15
Upside: +86.05%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.14
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.36
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $15.81
Upside: -36.75%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $24.98
Upside: -7.93%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.33
Upside: +50.15%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.39
Upside: +198.19%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.90
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $15.72
Upside: +154.45%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $5.41
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.09
Upside: +29.45%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.14
Upside: -12.47%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $46.26
Upside: +29.70%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.71
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $148.14
Upside: +112.64%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $73.84
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $227.72
Upside: +16.37%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.11
Upside: +313.63%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $10.38
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $2.36
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $29.19
Upside: -58.89%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $19.91
Upside: -